Oestrogen directly inhibits the cardiovascular L-type Ca2+ channel Cav1.2

Biochemical and Biophysical Research Communications

Volumn 361, Issue 2, 2007, Pages 522-527

  Ullrich, Nina D ^a,b   Koschak, Alexandra ^c   MacLeod, Kenneth T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Heterologous expression; Hormones; L type Ca2+ channel; Oestrogen; Whole cell patch clamp

Indexed keywords

CADMIUM; CALCIUM CHANNEL L TYPE; ESTRADIOL; ESTROGEN; NIFEDIPINE;

ARTICLE; CHANNEL GATING; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEMBRANE CURRENT; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

CADMIUM CHLORIDE; CALCIUM CHANNELS, L-TYPE; CARDIOVASCULAR SYSTEM; CELL LINE; ESTRADIOL; ESTROGENS; HUMANS; ION CHANNEL GATING; NIFEDIPINE; TRANSFECTION;

EID: 34547547094     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.07.054     Document Type: Article

References (26)

1. Grohe C., Kahlert S., Lobbert K., and Vetter H. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J. Endocrinol. 156 (1998) R1-R7
2. Heilberg I.P., Hernandez E., Alonzo E., Valera R., Ferreira L.G., Gomes S.A., Bellorin-Font E., and Weisinger J.R. Oestrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren. Fail. 27 (2005) 155-161
3. Toran-Allerand C.D. Oestrogen and the brain: beyond ER-alpha and ER-beta. Exp. Gerontol. 39 (2004) 1579-1586
4. Toran-Allerand C.D. Oestrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-oestradiol. Ann. NY Acad. Sci. 1052 (2005) 136-144
5. Lakoski S.G., and Herrington D.M. Effects of oestrogen receptor-active compounds on lipid metabolism. Diabetes Obes. Metab. 7 (2005) 471-477
6. Ling S., Komesaroff P., and Sudhir K. Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin. Sci. (Lond.) 111 (2006) 107-118
7. Mendelsohn M.E., and Karas R.H. The protective effects of oestrogen on the cardiovascular system. N. Engl. J. Med. 340 (1999) 1801-1811
8. Lawlor D.A., Timpson N., Ebrahim S., Day I.N.M., and Smith G.D. The association of oestrogen receptor alpha-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study. Eur. Heart J. 27 (2006) 1597-1604
9. Guo X., Razandi M., Pedram A., Kassab G., and Levin E.R. Oestrogen induces vascular wall dilation: Mediation through kinase signaling to nitric oxide and oestrogen receptors apha and beta. J. Biol. Chem. 280 (2005) 19704-19710
10. Lissin L.W., and Cooke J.P. Phytoestrogens and cardiovascular health. J. Am. Coll. Cardiol. 35 (2000) 1403-1410
11. Levin E.R. Cellular functions of the plasma membrane oestrogen receptor. Trends Endocrinol. Metab. 10 (1999) 374-377
12. Kelly M.J., and Levin E.R. Rapid actions of plasma membrane oestrogen receptors. Trends Endocrinol. Metab. 12 (2001) 152-156
13. Dick G.M., and Sanders K.M. (Xeno)estrogen sensitivity of smooth muscle BK channels conferred by the regulatory beta1 subunit: a study of beta1 knockout mice. J. Biol. Chem. 276 (2001) 44835-44840
14. Valverde M.A., Rojas P., Amigo J., Cosmelli D., Orio P., Bahamonde M.I., Mann G.E., Vergara C., et al. Acute activation of Maxi-K channels (hSlo) by oestradiol binding to the beta subunit. Science 285 (1999) 1929-1931
15. Wu T.W., Wang J.M., Chen S., and Brinton R.D. 17beta-oestradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-AMP response element binding protein signal pathway and BCL-2 expression in rat hippocampal neurons: a potential initiation mechanism for oestrogen-induced neuroprotection. Neuroscience 135 (2005) 59-72
16. Jiang C., Poole-Wilson P.A., Sarrel P.M., Mochizuki S., Collins P., and Macleod K.T. Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br. J. Pharmacol. 106 (1992) 739-745
17. Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P., and Mark M. Effect of single and compound knockouts of oestrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127 (2000) 4277-4291
18. Burow M.E., Boue S.M., Collins-Burow B.M., Melnik L.I., Duong B.N., Carter-Wientjes C.H., Li S., Wiese T.E., et al. Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through oestrogen receptor alpha and beta. J. Clin. Endocrinol. Metab. 86 (2001) 1750-1758
19. Herzig S., Khan I.F.Y., Gruendemann D., Matthes J., Ludwig A., Michels G., Hoppe U.C., Chaudhuri D., Schwartz A., Yue D.T., and Hullin R. Mechanism of Cav1.2 channel modulation by the amino terminus of cardiac ß2-subunits. FASEB J. 21 (2007) 1527-1538
20. Meyer R., Linz K.W., Surges R., Meinardus S., Vees J., Hoffmann A., Windholz O., and Grohe C. Rapid modulation of L-type calcium current by acutely applied oestrogens in isolated cardiac myocytes from human, guinea-pig and rat. Exp. Physiol. 83 (1998) 305-321
21. Scragg J.L., Jones R.D., Channer K.S., Jones T.H., and Peers C. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochem. Biophys. Res. Commun. 318 (2004) 503-506
22. Liew R., Stagg M.A., MacLeod K.T., and Collins P. Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current. Br. J. Pharmacol. 142 (2004) 89-96
23. Scragg J.L., Dallas M.A., and Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium 42 (2007) 11-15
24. N.D. Ullrich, H. Ria, M. Edenbrow, A. Krust, P. Collins, K.T. MacLeod, Genomic deletion of oestrogen receptors ER alpha and beta does not alter oestrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes, J. Pharmacol. Exp. Ther. (2007), submitted for publication.
25. Clancy C.E., Zhu Z.I., and Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H66-H75
26. Muchmore D.B. Raloxifene: a selective oestrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5 (2000) 388-392